- Home
- MRLN vs CGEM Comparison
MRLN vs CGEM Comparison
Compare MRLN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRLN | CGEM |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | 109 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 915.1M | 904.7M |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MRLN | CGEM |
|---|---|---|
| Price | $8.00 | $14.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $25.00 | ★ $30.13 |
| AVG Volume (30 Days) | ★ 1.4M | 713.9K |
| Earning Date | 10-28-2021 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.88 | $5.68 |
| 52 Week High | $17.00 | $16.74 |
Technical Indicators
Market Signals| Indicator | MRLN | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 41.10 | 54.60 |
| Support Level | $6.22 | $11.92 |
| Resistance Level | $17.00 | $15.66 |
| Average True Range (ATR) | 1.44 | 0.98 |
| MACD | -0.44 | 0.13 |
| Stochastic Oscillator | 7.38 | 62.78 |
Price Performance
Historical ComparisonAbout MRLN Merlin Inc. Common Stock
Merlin Inc is focused on developing autonomous flight software for legacy and next-generation airborne systems. Its aircraft-agnostic, AI-based software supports takeoff-to-landing autonomous operations for military and civil aviation programs. The company aims to build an AI-based operating software platform intended to support autonomous flight operations across a range of aircraft types.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.